about
Pros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesSignal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapyIntratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy.Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single doseParticle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I InterferonNovel immunotherapies for the treatment of melanoma.From the RNA world to the clinic.CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells.Mechanism of action of mRNA-based vaccines.Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide.Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.A new developing class of gene delivery: messenger RNA-based therapeutics.mRNA vaccines - a new era in vaccinology.mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopesThe Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
P2860
Q27013679-A215D1BF-A8DB-4991-B382-5AAD9F099D57Q28080262-FE3EECA4-C2A9-4C09-B1DC-E611CB2B3BECQ34654430-B9881F82-0379-44DB-A999-8099818F19FEQ35799289-7664A302-0174-4D4D-AFF7-71F84C3E4EB6Q37126611-2FC39EF4-25A0-4BCA-8E20-79DFB13EA953Q37254639-4773A2EB-E5B9-4A02-8D93-F2D002F0B35CQ38824190-89AD1EEB-BFE4-4EF7-A290-D6DB23BBDC8CQ38851919-1C1C9556-D2C7-4383-BE36-890A1AFEDCA1Q38853141-BF504837-2175-40F2-959B-CB072008BCE2Q38994510-B46B74CA-E724-4CFC-A17A-7650E19773F6Q39431058-0EA4D0C0-98EE-4911-A2C6-D91171F2837AQ40240339-B3B20940-257E-49B6-97A3-5677C825E4FFQ42925679-A56E4EC6-B401-4624-A016-AF35414CCF75Q45873514-BD083AA0-40D3-4F13-96B1-979ED15B8831Q47736893-639B3544-306D-48A8-97DF-9C49BE498C6AQ49715007-FB12D60C-6FE6-40C3-88DD-31E37A934121Q58708239-3A2C2D93-2B89-48BF-B987-17730650A491Q58750585-8B566654-F499-4A87-A904-0A2BA587DF53
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The ReNAissanCe of mRNA-based cancer therapy.
@en
type
label
The ReNAissanCe of mRNA-based cancer therapy.
@en
prefLabel
The ReNAissanCe of mRNA-based cancer therapy.
@en
P2093
P2860
P50
P1476
The ReNAissanCe of mRNA-based cancer therapy.
@en
P2093
Carlo Heirman
Dries Renmans
Kris Thielemans
Sandra Van Lint
P2860
P304
P356
10.1586/14760584.2015.957685
P577
2014-09-29T00:00:00Z